Cartalax

Overview

Cartalax (Ala-Glu-Asp) is a synthetic tripeptide bioregulator from the Khavinson peptide family, designed to support cartilage and connective tissue maintenance. It is part of a larger class of short peptides developed through decades of Russian bioregulator research targeting specific tissue types.

Mechanism of Action

Cartalax is proposed to interact with DNA at specific gene promoter regions, influencing the expression of genes involved in cartilage matrix synthesis and chondrocyte function. As a bioregulator peptide, it is theorized to act as an epigenetic modulator that normalizes gene expression patterns associated with healthy cartilage homeostasis.

Research Context

Research from the Khavinson group suggests that short peptide bioregulators can penetrate cells, enter the nucleus, and bind to specific DNA sequences to modulate gene expression. While this mechanism is not universally accepted, the peptides have shown biological activity in various tissue models.

Key Research Areas

Considerations for Researchers

Very short peptide (3 amino acids), highly stable. Oral bioavailability is proposed for this class of bioregulators. Available from fewer vendors. Independent verification of claimed mechanisms is recommended.